Diacerein for fatty liver disease
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests a medication called diacerein to see if it can help people with a type of fatty liver disease called MASLD. If you have fatty liver that is not caused by alcohol or other illnesses, this study may be a good fit for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have a confirmed diagnosis of metabolic fatty liver disease (MASLD).
- You do not have other liver diseases like hepatitis B or C.
- You drink less than 1 to 2 alcoholic drinks per day (no heavy drinking).
- You have not used certain diabetes or liver medications in the last 3 months.
- You are not pregnant, breastfeeding, or planning pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether dihydroartemisinin, a malaria drug that may reduce liver fat, helps people with metabolic fatty liver disease. It is for adults aged 18 to 45 who have a fatty liver and at least one metabolic problem like overweight, high blood pressure, or diabetes.
This trial tests a digital health app designed to help people with metabolic-associated fatty liver disease (MAFLD). The app provides diet and exercise guidance to improve liver health.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
This trial tests whether a probiotic mixture can improve liver health in people with moderate fatty liver disease (MASLD). It looks at how the probiotic affects liver fat, inflammation, and metabolism.
This study tests whether aspirin can help people with MASLD, a type of fatty liver disease linked to conditions like diabetes and obesity. It aims to see if aspirin can improve liver health without causing harm.
Hear when a new MAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.